Johnson & Johnson is making another major bet on Montgomery County, writes Harold Brubaker for The Philadelphia Inquirer.
The pharmaceutical giant announced plans to invest more than $1 billion to build a new cell therapy manufacturing facility in Lower Gwynedd Township near its Spring House campus. The plant is expected to create about 500 jobs when fully operational in 2031.
The facility will focus on producing advanced cell therapies for cancer treatment, including therapies targeting multiple myeloma, a cancer that affects white blood cells in bone marrow. Cell therapy uses engineered immune cells to fight disease, one of the fastest-growing areas in medicine.
The investment builds on Johnson & Johnson’s deep roots in Montgomery County. Its Johnson & Johnson Spring House research campus already employs roughly 2,500 scientists and serves as the company’s largest R&D center.
Governor Josh Shapiro said the state is offering $41.5 million in support for the project, calling it another step in cementing Pennsylvania’s leadership in life sciences manufacturing.
The announcement comes amid a wave of pharmaceutical expansion across the region, including new projects by Eli Lilly, GSK, and Merck.
Montco is already one of the nation’s top counties for pharmaceutical jobs. The new facility further strengthens its status as a biotech powerhouse.
To learn more about the new pharmaceutical facility, visit The Philadelphia Inquirer.
